Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 107

1.

Developing biomarkers in mood disorders research through the use of rapid-acting antidepressants.

Niciu MJ, Mathews DC, Nugent AC, Ionescu DF, Furey ML, Richards EM, Machado-Vieira R, Zarate CA Jr.

Depress Anxiety. 2014 Apr;31(4):297-307. doi: 10.1002/da.22224. Epub 2013 Dec 18. Review.

2.

Biomarkers in mood disorders research: developing new and improved therapeutics.

Niciu MJ, Mathews DC, Ionescu DF, Richards EM, Furey ML, Yuan P, Nugent AC, Henter ID, Machado-Vieira R, Zarate CA Jr.

Rev Psiquiatr Clin. 2014;41(5):131-134.

3.

Human biomarkers of rapid antidepressant effects.

Zarate CA Jr, Mathews DC, Furey ML.

Biol Psychiatry. 2013 Jun 15;73(12):1142-55. doi: 10.1016/j.biopsych.2012.11.031. Epub 2013 Jan 29. Review.

5.

Developing a clinical translational neuroscience taxonomy for anxiety and mood disorder: protocol for the baseline-follow up Research domain criteria Anxiety and Depression ("RAD") project.

Williams LM, Goldstein-Piekarski AN, Chowdhry N, Grisanzio KA, Haug NA, Samara Z, Etkin A, O'Hara R, Schatzberg AF, Suppes T, Yesavage J.

BMC Psychiatry. 2016 Mar 15;16:68. doi: 10.1186/s12888-016-0771-3.

6.

Potential of pretreatment neural activity in the visual cortex during emotional processing to predict treatment response to scopolamine in major depressive disorder.

Furey ML, Drevets WC, Hoffman EM, Frankel E, Speer AM, Zarate CA Jr.

JAMA Psychiatry. 2013 Mar;70(3):280-90. doi: 10.1001/2013.jamapsychiatry.60.

7.

Ketamine and rapid-acting antidepressants: a window into a new neurobiology for mood disorder therapeutics.

Abdallah CG, Sanacora G, Duman RS, Krystal JH.

Annu Rev Med. 2015;66:509-23. doi: 10.1146/annurev-med-053013-062946. Epub 2014 Oct 17. Review.

8.

Understanding and predicting suicidality using a combined genomic and clinical risk assessment approach.

Niculescu AB, Levey DF, Phalen PL, Le-Niculescu H, Dainton HD, Jain N, Belanger E, James A, George S, Weber H, Graham DL, Schweitzer R, Ladd TB, Learman R, Niculescu EM, Vanipenta NP, Khan FN, Mullen J, Shankar G, Cook S, Humbert C, Ballew A, Yard M, Gelbart T, Shekhar A, Schork NJ, Kurian SM, Sandusky GE, Salomon DR.

Mol Psychiatry. 2015 Nov;20(11):1266-85. doi: 10.1038/mp.2015.112. Epub 2015 Aug 18.

9.

Development and natural history of mood disorders.

Costello EJ, Pine DS, Hammen C, March JS, Plotsky PM, Weissman MM, Biederman J, Goldsmith HH, Kaufman J, Lewinsohn PM, Hellander M, Hoagwood K, Koretz DS, Nelson CA, Leckman JF.

Biol Psychiatry. 2002 Sep 15;52(6):529-42.

PMID:
12361667
10.

Glutamate receptor antagonists as fast-acting therapeutic alternatives for the treatment of depression: ketamine and other compounds.

Niciu MJ, Henter ID, Luckenbaugh DA, Zarate CA Jr, Charney DS.

Annu Rev Pharmacol Toxicol. 2014;54:119-39. doi: 10.1146/annurev-pharmtox-011613-135950. Review.

11.

The Road Ahead to Cure Alzheimer's Disease: Development of Biological Markers and Neuroimaging Methods for Prevention Trials Across all Stages and Target Populations.

Cavedo E, Lista S, Khachaturian Z, Aisen P, Amouyel P, Herholz K, Jack CR Jr, Sperling R, Cummings J, Blennow K, O'Bryant S, Frisoni GB, Khachaturian A, Kivipelto M, Klunk W, Broich K, Andrieu S, de Schotten MT, Mangin JF, Lammertsma AA, Johnson K, Teipel S, Drzezga A, Bokde A, Colliot O, Bakardjian H, Zetterberg H, Dubois B, Vellas B, Schneider LS, Hampel H.

J Prev Alzheimers Dis. 2014 Dec;1(3):181-202.

12.

The promise of ketamine for treatment-resistant depression: current evidence and future directions.

DeWilde KE, Levitch CF, Murrough JW, Mathew SJ, Iosifescu DV.

Ann N Y Acad Sci. 2015 May;1345:47-58. doi: 10.1111/nyas.12646. Epub 2015 Feb 3. Review.

13.

Mood Therapeutics: Novel Pharmacological Approaches for Treating Depression.

Henter ID, de Sousa RT, Gold PW, Brunoni AR, Zarate CA Jr, Machado-Vieira R.

Expert Rev Clin Pharmacol. 2017 Feb;10(2):153-166. doi: 10.1080/17512433.2017.1253472. Epub 2017 Jan 16. Review.

14.

Pretreatment Differences in BOLD Response to Emotional Faces Correlate with Antidepressant Response to Scopolamine.

Furey ML, Drevets WC, Szczepanik J, Khanna A, Nugent A, Zarate CA Jr.

Int J Neuropsychopharmacol. 2015 Mar 28;18(8). pii: pyv028. doi: 10.1093/ijnp/pyv028.

15.

ECNP consensus meeting. Bipolar depression. Nice, March 2007.

Goodwin GM, Anderson I, Arango C, Bowden CL, Henry C, Mitchell PB, Nolen WA, Vieta E, Wittchen HU.

Eur Neuropsychopharmacol. 2008 Jul;18(7):535-49. doi: 10.1016/j.euroneuro.2008.03.003. Epub 2008 May 23. Review.

PMID:
18501566
16.

Further development of biomarkers in amyotrophic lateral sclerosis.

Blasco H, Vourc'h P, Pradat PF, Gordon PH, Andres CR, Corcia P.

Expert Rev Mol Diagn. 2016 Aug;16(8):853-68. doi: 10.1080/14737159.2016.1199277. Epub 2016 Jun 20. Review.

PMID:
27275785
17.

Ketamine: promising path or false prophecy in the development of novel therapeutics for mood disorders?

Sanacora G, Schatzberg AF.

Neuropsychopharmacology. 2015 Jan;40(2):259-67. doi: 10.1038/npp.2014.261. Epub 2014 Sep 26. Review. Erratum in: Neuropsychopharmacology. 2015 Apr;40(5):1307.

18.

Genetics and pharmacogenetics of mood disorders.

Serretti A.

Psychiatr Pol. 2017 Apr 30;51(2):197-203. doi: 10.12740/PP/68914. Epub 2017 Apr 30. Review. English, Polish.

19.

The Role of Muscarinic Receptors in the Pathophysiology of Mood Disorders: A Potential Novel Treatment?

Jeon WJ, Dean B, Scarr E, Gibbons A.

Curr Neuropharmacol. 2015;13(6):739-49. Review.

20.

Pharmacogenomics in the treatment of mood disorders: Strategies and Opportunities for personalized psychiatry.

Amare AT, Schubert KO, Baune BT.

EPMA J. 2017 Sep 5;8(3):211-227. doi: 10.1007/s13167-017-0112-8. eCollection 2017 Sep. Review.

Supplemental Content

Support Center